EverSource Wealth Advisors’s Taysha Gene Therapies TSHA Stock Holding History

EverSource Wealth Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$960	Hold	141	–	–	﹤0.01%	3976
2026 Q1	$630	Buy	141 +50	+55%	+$232	﹤0.01%	4003
2025 Q4	$501	Hold	91	–	–	﹤0.01%	3879
2025 Q3	$298	Sell	91 -114	-56%	-$323	﹤0.01%	4050
2025 Q2	$473	Sell	205 -167	-45%	-$363	﹤0.01%	3912
2025 Q1	$517	Buy	+372	New	+$622	﹤0.01%	3450

Other funds holding TSHA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EverSource Wealth Advisors's TSHA Position: Q2 2026 in Review

EverSource Wealth Advisors held its Taysha Gene Therapies (TSHA) position steady in Q2 2026 at 141 shares worth $960. The position accounts for ﹤0.01% of the portfolio, ranked #3976.

EverSource Wealth Advisors first reported a position in TSHA in Q1 2025 and has held it in 6 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

EverSource Wealth Advisors held 141 shares of Taysha Gene Therapies worth $960 as of Q2 2026.
EverSource Wealth Advisors left its Taysha Gene Therapies share count unchanged in Q2 2026.
Taysha Gene Therapies made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #3976 holding.
EverSource Wealth Advisors first reported a position in Taysha Gene Therapies in Q1 2025 and has held it in 6 quarters since.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.